Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - H.C. Wainwright has assumed coverage on Valneva (EPA:VLS) SE (NASDAQ:VALN) with a Buy rating and a price target of $18.00, according to a research note released Tuesday. The stock, which has surged 177% year-to-date and is trading near its 52-week high of $12.20, has shown remarkable momentum in recent months.
The firm highlighted Valneva’s co-development of VLA15, a Phase 3 Lyme disease vaccine being developed globally in partnership with Pfizer (NYSE:PFE). Pivotal data from this program is expected by year-end 2025, with regulatory submissions anticipated in 2026 and potential commercial launch in 2027.
H.C. Wainwright analyst Brandon Folkes noted that VLA15 offers "a de-risked, relatively high-probability path to potential blockbuster sales," with Valneva retaining mid-teens to low-20s royalties and eligibility for up to $408 million in milestone payments.
The research firm believes the VLA15 program alone creates a favorable risk-reward profile for Valneva’s stock valuation, with additional upside potential from the company’s three approved proprietary travel vaccines.
Valneva, described as a commercial-stage vaccine company with a strong proprietary portfolio, also has two novel clinical-stage infectious disease programs in development beyond its Lyme disease candidate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.